Advertisement

Alterations in intraocular cytokine levels following intravitreal ranibizumab

      Abstract

      Objective

      Our previous work has shown that, after intravitreal bevacizumab (IVB) administration, decreases in the levels of vascular endothelial growth factor (VEGF)-A and placental growth factor (PlGF), along with increases in the levels of interleukin (IL)-8 and transforming growth factor (TGF)-β2, can be observed. It is not yet known if similar changes occur after intravitreal ranibizumab (IVR). The purpose of this study was to examine intraocular cytokine changes after IVR.

      Design

      Prospective clinical study.

      Participants

      Subjects with proliferative diabetic retinopathy requiring pars plana vitrectomy (PPV) were recruited.

      Methods

      Participants received IVR as pre-treatment before PPV. Aqueous humour levels of IL-8, VEGF-A, PlGF, and TGF-β2 were measured at time of pre-treatment and PPV. Results were analyzed using univariate statistical models.

      Results

      A total of 14 participants were recruited. After IVR administration, we observed a decrease in the levels of VEGF-A and PlGF, and an increase in the levels of IL-8 and TGF-β2. These results were statistically significant only for VEGF-A (p = 0.0001) and IL-8 (p = 0.0002).

      Conclusions

      The changes in cytokine levels after IVR mirror the changes seen after IVB. Further studies are warranted in order to determine if there are any differences between IVB and IVR in this regard.

      Objectif

      Nos travaux antérieurs ont montré que, suite à l'administration de bevacizumab intravitréen (BIV), on constate une diminution des niveaux de FCEA-A et du facteur de croissance placentaire (PlGF), et une augmentation des niveaux d'IL-8 et de TGF-β2. Nous ne savons pas encore si des changements similaires se produisent suite à l'administration de ranibizumab intravitréen (RIV). Le but de l'étude était d'examiner les changements au niveau des cytokines intraoculaires après l'administration de RIV.

      Nature

      Étude clinique prospective.

      Participants

      Nous avons recruté des sujets atteints de rétinopathie diabétique proliférante (RDP) nécessitant une vitrectomie par la pars plana (VPP).

      Méthodes

      Les participants ont reçu du RIV comme prétraitement avant de subir une VPP. Nous avons mesuré le niveau d'humeur aqueuse de l'IL-8, du FCEA-A, du PlGF et du TGF-β2 au moment du prétraitement et de la VPP. Nous avons analysé les résultats à l'aide de modèles statistiques univariés.

      Résultats

      Au total, 14 participants ont été recrutés. Après l'administration du RIV, nous avons observé une diminution des niveaux de FCEA-A et de PlGF, et une augmentation des taux d'IL-8 et de TGF-β2. Nous n'avons constaté des résultats statistiquement significatifs que pour le FCEA-A (p = 0,0001) et l'IL-8 (p = 0,0002).

      Conclusion

      Les changements au niveau des cytokines après l'administration de RIV sont semblables aux changements observés après l'administration de BIV. D'autres études sont nécessaires afin de déterminer s'il y a des différences entre le BIV et le RIV à cet égard.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chakravarthy U.
        • Harding S.P.
        • Rogers C.A.
        • et al.
        Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.
        Lancet. 2013; 382: 1258-1267
        • Nepomuceno A.B.
        • Takaki E.
        • Paes de Almeida FP
        • et al.
        A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema.
        Am J Ophthalmol. 2013; 156: e502
        • Zou L.
        • Lai H.
        • Zhou Q.
        • Xiao F.
        Lasting controversy on ranibizumab and bevacizumab.
        Theranostics. 2011; 1: 395-402
        • Jonas J.B.
        • Tao Y.
        • Neumaier M.
        • Findeisen P.
        Cytokine concentration in aqueous humour of eyes with exudative age-related macular degeneration.
        Acta Ophthalmol. 2012; 90: e381-e388
        • Jonas J.B.
        • Tao Y.
        • Neumaier M.
        • Findeisen P.
        Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration.
        Arch Ophthalmol. 2010; 128: 1281-1286
        • Owen L.A.
        • Hartnett M.E.
        Soluble mediators of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema.
        Curr Diab Rep. 2013; 13: 476-480
        • Jung S.H.
        • Kim K.A.
        • Sohn S.W.
        • Yang S.J.
        Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion.
        Invest Ophthalmol Vis Sci. 2014; 55: 2290-2296
        • Feng J.
        • Zhao T.
        • Zhang Y.
        • Ma Y.
        • Jiang Y.
        Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion.
        PLoS One. 2013; 8: e68149
        • Forooghian F.
        • Kertes P.J.
        • Eng K.T.
        • Agron E.
        • Chew E.Y.
        Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.
        Invest Ophthalmol Vis Sci. 2010; 51: 2388-2392
        • Jeon S.
        • Lee W.K.
        Intravitreal bevacizumab increases intraocular interleukin-6 levels at 1 day after injection in patients with proliferative diabetic retinopathy.
        Cytokine. 2012; 60: 535-539
        • Sohn H.J.
        • Han D.H.
        • Lee D.Y.
        • Nam D.H.
        Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.
        Acta Ophthalmol. 2014; 92: e217-e224
        • Jeon S.
        • Lee W.K.
        • Jung Y.
        Changes in the intraocular cytokine levels after intravitreal bevacizumab in uveitic macular edema.
        Ocul Immunol Inflamm. 2012; 20: 360-364
        • Sohn H.J.
        • Han D.H.
        • Kim I.T.
        • et al.
        Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema.
        Am J Ophthalmol. 2011; 152: 686-694
        • Funk M.
        • Karl D.
        • Georgopoulos M.
        • et al.
        Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
        Ophthalmology. 2009; 116: 2393-2399
        • Carmeliet P.
        • Moons L.
        • Luttun A.
        • et al.
        Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.
        Nat Med. 2001; 7: 575-583
        • Papadopoulos N.
        • Martin J.
        • Ruan Q.
        • et al.
        Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.
        Angiogenesis. 2012; 15: 171-185
        • Mizukami Y.
        • Kohgo Y.
        • Chung D.C.
        Hypoxia inducible factor-1 independent pathways in tumor angiogenesis.
        Clin Cancer Res. 2007; 13: 5670-5674
        • Mizukami Y.
        • Jo W.S.
        • Duerr E.M.
        • et al.
        Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells.
        Nat Med. 2005; 11: 992-997
        • Mitamura Y.
        • Tashimo A.
        • Nakamura Y.
        • et al.
        Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
        Diabetes Care. 2002; 25: 2352
        • Roh M.I.
        • Kim H.S.
        • Song J.H.
        • Lim J.B.
        • Koh H.J.
        • Kwon O.W.
        Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment.
        Retina. 2009; 29: 523-529
        • Jonas J.B.
        • Jonas R.A.
        • Neumaier M.
        • Findeisen P.
        Cytokine concentration in aqueous humor of eyes with diabetic macular edema.
        Retina. 2012; 32: 2150-2157